title: FPTIII mitigates peroxisome-mediated oxidative stress in kidneys of spontaneously hypertensive diabetic rats.
abstract: OBJECTIVE
  Peroxisomes are known to play a role in cellular oxidative stress during pathogenesis of diabetes and hypertension. We reported earlier that FPTIII (a farnesyl protein transferase inhibitor) attenuates ischemia-reperfusion injury and renal dysfunction in diabetic hypertensive (DH) rats. In this study, we have examined the effect of FPTIII on peroxisomal enzymes in relation to oxidative stress in kidneys of DH rats.
  
  
  METHODS
  Male Wistar-Kyoto (WKY) and spontaneously hypertensive (SHR) rats were treated with streptozotocin (STZ) and/or FPTIII. Activities of key peroxisomal enzymes, catalase, acyl-CoA oxidase and beta-oxidation of lignoceric acid were measured in kidney homogenates. Lipid peroxidation in kidney was measured by malondialdehyde (MDA) assay.
  
  
  RESULTS
  Catalase activity was significantly (p < 0.01) reduced in diabetic WKY or SHR, and FPTIII markedly attenuated (p < 0.01) diabetes-induced inhibition of catalase. FPTIII also reduced STZ-induced increase in acyl-CoA oxidase activity. Fatty acid beta-oxidation and lipid peroxides were significantly increased in kidneys of DH rats. FPTIII reduced (p < 0.01) diabetes and hypertension-induced increase in fatty acid oxidation and lipid peroxides.
  
  
  CONCLUSIONS
  Our results suggest that farnesyl transferase inhibition modulates peroxisome enzyme activities and alleviates oxidative stress, thus providing a possible mechanism for reported FPTIII-mediated protection against renal dysfunction in DH rats.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Kuwait University, Safat, Kuwait. dhaunsig @ hsc.edu.kw
authors.forename: Gursev S
authors.initials: GS
authors.lastname: Dhaunsi
authors.forename: Mariam H M
authors.initials: MH
authors.lastname: Yousif
authors.forename: Ibrahim F
authors.initials: IF
authors.lastname: Benter
mesh_terms: D042962:Acyl-CoA Oxidase / Q000378:metabolism; D000818:Animals; D002374:Catalase / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy* / Q000378:metabolism; D004789:Enzyme Activation / Q000187:drug effects; D005227:Fatty Acids / Q000378:metabolism; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000378:metabolism; D007668:Kidney / Q000201:enzymology; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D063065:Organophosphonates / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects*; D020675:Peroxisomes / Q000378:metabolism*; D051381:Rats; D011918:Rats, Inbred SHR; D011921:Rats, Inbred WKY; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: C436083:2-(2-oxo-2-((3,7,11-trimethyl-2,6,10-dodecatrienyl)oxy)aminoethyl)phosphonic acid, (2,2-dimethyl-1-oxopropoxy)methyl ester sodium; D005227:Fatty Acids; D063065:Organophosphonates; D017382:Reactive Oxygen Species; D002374:Catalase; D042962:Acyl-CoA Oxidase; C010210:lignoceric acid